Ongoing Trials in First-Line and Peri-Radiotherapy for Nasopharyngeal Carcinoma
The Tori-013 trial (ChiCTR2200055494) is actively investigating shortened-duration PD-1 blockade with toripalimab combined with induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma, representing the most relevant ongoing trial evaluating immunotherapy in the peri-radiotherapy setting 1.
Key Ongoing Trial Details
Tori-013 Study Design
This multicenter phase II randomized trial is evaluating:
- Population: Stage III/IVa nasopharyngeal carcinoma (estimated n=154)
- Intervention: Toripalimab 240 mg Q3W during induction chemotherapy (gemcitabine + cisplatin) and concurrent chemoradiotherapy (cisplatin + radiotherapy ≥70 Gy), followed by two additional cycles post-radiotherapy
- Control: Same chemotherapy/radiotherapy regimen with placebo
- Primary endpoint: 3-year progression-free survival
- Secondary endpoints: Overall survival, objective response rate, EBV DNA dynamics, lymphocyte subset changes, and safety 1
Context Within Current Treatment Landscape
First-Line Metastatic Disease
The guideline framework already supports PD-1 inhibitor integration in first-line metastatic disease. Two phase III trials demonstrated progression-free survival improvements when camrelizumab or toripalimab were added to cisplatin-gemcitabine chemotherapy followed by maintenance immunotherapy 2. This represents established practice rather than ongoing investigation.
Peri-Radiotherapy Setting
The Tori-013 trial addresses a critical knowledge gap: the optimal duration and timing of immunotherapy combined with definitive chemoradiotherapy for locally advanced disease 1. This differs from the adjuvant immunotherapy approach evaluated in the completed "Dipper" trial, which showed 89% versus 80% 3-year event-free survival with adjuvant camrelizumab versus placebo after induction therapy and definitive chemoradiotherapy 3.
Emerging Evidence Supporting These Investigations
Recent data suggest specific patient populations may derive particular benefit from immunotherapy integration:
High-risk features: Patients with high-grade extranodal extension (G2/3-rENE) showed superior complete response rates (21.15% vs 7.96%) and 2-year progression-free survival (93.2% vs 81.0%) when PD-1 inhibitors were added to induction chemotherapy 4
Baseline characteristics: Patients with EBV DNA <400 IU/mL, LDH <2×ULN, T3-4 or N2-3 stage, stage IVa disease, and G3-rENE demonstrated greater benefit from combined treatment 4
Clinical Implications
The Tori-013 trial specifically tests whether shortened immunotherapy duration during the curative treatment phase can enhance efficacy while maintaining tolerability, addressing concerns about prolonged immunotherapy exposure and associated toxicities 1. This streamlined approach contrasts with maintenance strategies extending beyond definitive treatment.
The trial's focus on lymphocyte subset dynamics as a secondary endpoint reflects emerging understanding that post-treatment immune profiling, particularly CD4+/CD8+ ratios, may predict treatment response 4.